MARKET

BHVN

BHVN

Biohaven Pharma
NYSE

Real-time Quotes | Nasdaq Last Sale

51.08
+2.06
+4.20%
After Hours: 51.08 0 0.00% 16:25 11/15 EST
OPEN
49.52
PREV CLOSE
49.02
HIGH
51.50
LOW
48.96
VOLUME
884.70K
TURNOVER
--
52 WEEK HIGH
67.86
52 WEEK LOW
29.17
MARKET CAP
2.67B
P/E (TTM)
-5.7098
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BHVN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BHVN News

  • Biohaven Readies for ‘David Versus Goliath’ Battle with Allergan
  • Bloomberg.2d ago
  • Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting
  • PR Newswire.11/06 14:02
  • Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole
  • PR Newswire.11/05 12:30
  • Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board
  • PR Newswire.11/04 23:43

More

Industry

Biotechnology & Medical Research
+1.19%
Pharmaceuticals & Medical Research
+1.32%

Hot Stocks

Name
Price
%Change

About BHVN

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.
More

Webull offers Biohaven Pharmaceutical Holding Co Ltd (BHVN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.